|
Report ID
|
29274 |
|
Drug Identification Number
|
01927604 |
|
Brand name
|
MYOCHRYSINE |
|
Common or Proper name
|
Myochrisine 50mg/1ml |
|
Company Name
|
SANOFI-AVENTIS CANADA INC |
|
Market Status
|
CANCELLED POST MARKET |
|
Active Ingredient(s)
|
GOLD SODIUM THIOMALATE |
|
Strength(s)
|
50MG |
|
Dosage form(s)
|
SOLUTION |
|
Route of administration
|
INTRAMUSCULAR |
|
Packaging size
|
5 |
|
ATC code
|
M01CB |
|
ATC description
|
SPECIFIC ANTIRHEUMATIC AGENTS |
|
Reason for shortage
|
Shortage of an active ingredient. |
|
Anticipated start date
|
2017-11-24 |
|
Actual start date
|
2017-12-01 |
|
Estimated end date
|
2019-09-30 |
|
Actual end date
|
2019-06-04 |
|
Shortage status
|
Resolved |
|
Updated date
|
2019-06-10 |
|
Company comments
|
The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. |
|
Health Canada comments
|
|
|
Tier 3 Status
|
No |
| Company contact information |
email: [email protected]
Telephone: 1-800-265-7927 |
